Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

266 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Potent Plasmablast-Derived Antibodies Elicited by the National Institutes of Health Dengue Vaccine.
Magnani DM, Silveira CGT, Ricciardi MJ, Gonzalez-Nieto L, Pedreño-Lopez N, Bailey VK, Gutman MJ, Maxwell HS, Domingues A, Costa PR, Ferrari L, Goulart R, Martins MA, Martinez-Navio JM, Fuchs SP, Kalil J, Timenetsky MDC, Wrammert J, Whitehead SS, Burton DR, Desrosiers RC, Kallas EG, Watkins DI. Magnani DM, et al. Among authors: watkins di. J Virol. 2017 Oct 27;91(22):e00867-17. doi: 10.1128/JVI.00867-17. Print 2017 Nov 15. J Virol. 2017. PMID: 28878078 Free PMC article. Clinical Trial.
Tat-vaccinated macaques do not control simian immunodeficiency virus SIVmac239 replication.
Allen TM, Mortara L, Mothé BR, Liebl M, Jing P, Calore B, Piekarczyk M, Ruddersdorf R, O'Connor DH, Wang X, Wang C, Allison DB, Altman JD, Sette A, Desrosiers RC, Sutter G, Watkins DI. Allen TM, et al. Among authors: watkins di. J Virol. 2002 Apr;76(8):4108-12. doi: 10.1128/jvi.76.8.4108-4112.2002. J Virol. 2002. PMID: 11907251 Free PMC article.
Immunization of rhesus macaques with a DNA prime/modified vaccinia virus Ankara boost regimen induces broad simian immunodeficiency virus (SIV)-specific T-cell responses and reduces initial viral replication but does not prevent disease progression following challenge with pathogenic SIVmac239.
Horton H, Vogel TU, Carter DK, Vielhuber K, Fuller DH, Shipley T, Fuller JT, Kunstman KJ, Sutter G, Montefiori DC, Erfle V, Desrosiers RC, Wilson N, Picker LJ, Wolinsky SM, Wang C, Allison DB, Watkins DI. Horton H, et al. Among authors: watkins di. J Virol. 2002 Jul;76(14):7187-202. doi: 10.1128/jvi.76.14.7187-7202.2002. J Virol. 2002. PMID: 12072518 Free PMC article. Clinical Trial.
Effects of cytotoxic T lymphocytes (CTL) directed against a single simian immunodeficiency virus (SIV) Gag CTL epitope on the course of SIVmac239 infection.
Allen TM, Jing P, Calore B, Horton H, O'Connor DH, Hanke T, Piekarczyk M, Ruddersdorf R, Mothé BR, Emerson C, Wilson N, Lifson JD, Belyakov IM, Berzofsky JA, Wang C, Allison DB, Montefiori DC, Desrosiers RC, Wolinsky S, Kunstman KJ, Altman JD, Sette A, McMichael AJ, Watkins DI. Allen TM, et al. Among authors: watkins di. J Virol. 2002 Oct;76(20):10507-11. doi: 10.1128/jvi.76.20.10507-10511.2002. J Virol. 2002. PMID: 12239328 Free PMC article.
Major histocompatibility complex class I alleles associated with slow simian immunodeficiency virus disease progression bind epitopes recognized by dominant acute-phase cytotoxic-T-lymphocyte responses.
O'Connor DH, Mothe BR, Weinfurter JT, Fuenger S, Rehrauer WM, Jing P, Rudersdorf RR, Liebl ME, Krebs K, Vasquez J, Dodds E, Loffredo J, Martin S, McDermott AB, Allen TM, Wang C, Doxiadis GG, Montefiori DC, Hughes A, Burton DR, Allison DB, Wolinsky SM, Bontrop R, Picker LJ, Watkins DI. O'Connor DH, et al. Among authors: watkins di. J Virol. 2003 Aug;77(16):9029-40. doi: 10.1128/jvi.77.16.9029-9040.2003. J Virol. 2003. PMID: 12885919 Free PMC article.
Multispecific vaccine-induced mucosal cytotoxic T lymphocytes reduce acute-phase viral replication but fail in long-term control of simian immunodeficiency virus SIVmac239.
Vogel TU, Reynolds MR, Fuller DH, Vielhuber K, Shipley T, Fuller JT, Kunstman KJ, Sutter G, Marthas ML, Erfle V, Wolinsky SM, Wang C, Allison DB, Rud EW, Wilson N, Montefiori D, Altman JD, Watkins DI. Vogel TU, et al. Among authors: watkins di. J Virol. 2003 Dec;77(24):13348-60. doi: 10.1128/jvi.77.24.13348-13360.2003. J Virol. 2003. PMID: 14645590 Free PMC article.
Public health. A sound rationale needed for phase III HIV-1 vaccine trials.
Burton DR, Desrosiers RC, Doms RW, Feinberg MB, Gallo RC, Hahn B, Hoxie JA, Hunter E, Korber B, Landay A, Lederman MM, Lieberman J, McCune JM, Moore JP, Nathanson N, Picker L, Richman D, Rinaldo C, Stevenson M, Watkins DI, Wolinsky SM, Zack JA. Burton DR, et al. Among authors: watkins di. Science. 2004 Jan 16;303(5656):316. doi: 10.1126/science.1094620. Science. 2004. PMID: 14726576 No abstract available.
HIV vaccine design: insights from live attenuated SIV vaccines.
Koff WC, Johnson PR, Watkins DI, Burton DR, Lifson JD, Hasenkrug KJ, McDermott AB, Schultz A, Zamb TJ, Boyle R, Desrosiers RC. Koff WC, et al. Among authors: watkins di. Nat Immunol. 2006 Jan;7(1):19-23. doi: 10.1038/ni1296. Nat Immunol. 2006. PMID: 16357854 Review.
266 results